Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings

"The Report Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

GBI Research, the leading business intelligence provider, has released its latest research on, “Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings”, which provides insights into the impact of biobetter therapies on the top selling biologic therapeutics, the regulatory procedure surrounding entry in the biobetters market and including recent technological advances that have driven advancement in the market. The report provides an in-depth analysis of top selling biobetter products covering top selling protein classes, erythropoietin’s, granulocyte-colony stimulating factors (G-CSF), interferon-α, interferon-beta, insulin and insulin analogs, monoclonal antibodies (mAbs) and tumor Necrosis Factor-α (TNF-α). The report also includes insights into the biobetter therapeutics R&D pipeline. It analyzes the competitive landscape, including Mergers and Acquisitions (M&As), and licensing and co-development deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research found that on average biobetter launches generate more revenues than their corresponding originator therapies. In some scenarios this extended to, the launch of a biobetter therapy substituting the sales from an existing originator product or biobetter therapy.

View Report @ https://www.marketresearchreports.biz/reports/125694/biobetters-in-key-s-market-research-reports

Scope

Data and analysis on the impact of biobetter therapeutics on the major top selling biologics erythropoietin’s, granulocyte-colony stimulating factors (G-CSF), interferon-α, interferon-beta, insulin and insulin analogs, human growth hormone and monoclonal and mAbs.
Pipeline analysis of biobetter therapies in major protein classes erythropoietin’s, G-CSF, interferon-α, interferon-beta, insulin and insulin analogs, mAbs and TNF-α.
Key drivers and restraints that have had a significant impact on the market.
The competitive landscape of the global biobetter therapeutics market, including companies such as Celgene, Amgen, Bristol-Myers Squibb, Amylin and Dainippon Sumitomo Pharma.
Key M&A activities and licensing and co-development agreements that took place from 2010-2012 in the global Biobetters market.

Get Sample Copy Of This Report @
https://www.marketresearchreports.biz/sample/sample/125694

Reasons to buy

Align your product portfolio to the markets with high growth potential.
Develop business strategies by understanding the trends shaping and driving technological advancements in the field of biobetter therapies.
Identify key molecules in development being used for biobetter therapies.
Reinforce R&D pipelines by identifying common drug class biobetters in the pipeline for top selling protein classes.
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/125694

Table of Content

1 Table of Contents
1.2 List of Tables
1.3 List of Figures

2 Executive Summary
2.1 The Launch of Biobetter Therapies has Resulted in Considerable Gains in the Global Market
2.2 A Strong Pipeline and the Entry of New Players will Intensify Competition
2.3 The Top Seven Companies are Major Players in the Global Biobetters Market
2.4 Strategic Consolidations have Led to the Entry of New Players in the Biobetter Therapeutics Market

3 Introduction
3.1 GBI Research Report Guidance

4 Global Market Overview
4.1 Biobetter Therapies Already on the Market
4.1.1 Erythropoietins
4.1.2 Granulocyte-colony Stimulating Factors
4.1.3 Interferon-a, Interferon-ß
4.1.4 Insulin and Insulin Analogs
4.1.5 Monoclonal Antibodies
4.1.6 TNF-a Inhibitors
4.2 Promising Drug Classes for Biobetter Therapies
4.2.1 Human Growth Hormone
4.3 Comparison of Biosimilars and Biobetters

5 Technology Analysis
5.1 Introduction
5.1.1 Host Cell
5.1.2 Glycosylation
5.1.3 PEGylation
5.1.4 Polysialylation
5.1.5 Fusion Protein
5.1.6 PASylation
5.1.7 HESylation

6 Challenges and Opportunities
6.1 Opportunities
6.1.1 Biobetter Therapies Gain Substantial Market Shares upon Launch
6.1.2 Higher Success Rates in the Development of Biobetter Therapies
6.2 Challenges
6.2.1 Uncertainty Surrounding the Implementation of the Affordable Care Act will Limit Patient Access to Biobetter Drugs
6.2.2 Growing Debts and the Slowing of the Economy will Drive Governmental Bodies and Healthcare Providers to Restrict the Use of Expensive Biobetter Therapies
6.2.3 Regulatory Policies in Emerging Economies such as China and India do not Provide Enough Protection for the Development of Biobetter Therapies

7 Pipeline Analysis
7.1 Introduction
7.2 Human Growth Hormone
7.3 Erythropoietin
7.4 Granulocyte-colony Stimulating Factor
7.5 Interferon-a and Interferon-ß
7.6 Insulin and Insulin Analogs
7.7 Monoclonal Antibodies
7.8 Promising Drugs
7.8.1 LB03002 - HGH
7.8.2 Degludec - Insulin Analog
7.8.3 Theracim - Monoclonal Antibody
7.8.4 Pertuzumab - Monoclonal Antibody
7.8.5 RG7159 - Monoclonal Antibody

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.